PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11257029-3	2001	The beta-lactamase activity against imipenem and meropenem was inhibited in the presence of clavulanic acid.	Meropenem	49-58	beta-lactamase	Klebsiella pneumoniae	4-18	
30128699-2	2018	Intravenous meropenem/vaborbactam (Vabomere ) is the first carbapenem/beta-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis.	Meropenem	12-21	beta-lactamase	Klebsiella pneumoniae	70-84	
30128699-3	2018	Vaborbactam is a potent inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of meropenem against beta-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.	Meropenem	112-121	beta-lactamase	Klebsiella pneumoniae	166-180	
30128699-3	2018	Vaborbactam is a potent inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of meropenem against beta-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.	Meropenem	148-157	beta-lactamase	Klebsiella pneumoniae	166-180	
30128699-4	2018	Meropenem/vaborbactam demonstrated excellent in vitro activity against Gram-negative clinical isolates, including KPC- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.	Meropenem	0-9	beta-lactamase	Klebsiella pneumoniae	141-155